Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities research analysts at Leerink Swann lowered their Q3 2017 earnings estimates for shares of Theravance Biopharma in a report released on Wednesday. Leerink Swann analyst G. Porges now anticipates that the biopharmaceutical company will post earnings per share of ($1.26) for the quarter, down from their prior estimate of ($1.09). Leerink Swann currently has a “Buy” rating and a $47.00 target price on the stock. Leerink Swann also issued estimates for Theravance Biopharma’s Q4 2017 earnings at ($1.31) EPS, FY2017 earnings at ($5.10) EPS, FY2018 earnings at ($4.83) EPS, FY2019 earnings at ($4.84) EPS and FY2020 earnings at ($3.37) EPS.

A number of other research firms have also issued reports on TBPH. Cantor Fitzgerald initiated coverage on Theravance Biopharma in a report on Friday, June 16th. They issued an “overweight” rating and a $55.00 target price for the company. ValuEngine upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Needham & Company LLC reiterated a “buy” rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd. Finally, BidaskClub lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. Theravance Biopharma has a consensus rating of “Hold” and an average price target of $41.13.

ILLEGAL ACTIVITY WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/q3-2017-eps-estimates-for-theravance-biopharma-inc-decreased-by-analyst-tbph/1471572.html.

Theravance Biopharma (NASDAQ TBPH) opened at 23.955 on Friday. The stock has a 50 day moving average price of $36.36 and a 200 day moving average price of $35.46. Theravance Biopharma has a 52-week low of $23.15 and a 52-week high of $43.44. The company’s market capitalization is $1.25 billion.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by $0.13. The company had revenue of $3.09 million during the quarter, compared to the consensus estimate of $5.07 million. Theravance Biopharma had a negative return on equity of 74.17% and a negative net margin of 742.59%.

Hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Theravance Biopharma during the fourth quarter worth about $464,000. Teachers Advisors LLC increased its stake in shares of Theravance Biopharma by 19.2% in the fourth quarter. Teachers Advisors LLC now owns 69,563 shares of the biopharmaceutical company’s stock worth $2,218,000 after buying an additional 11,201 shares during the period. Wells Fargo & Company MN increased its stake in shares of Theravance Biopharma by 10.6% in the first quarter. Wells Fargo & Company MN now owns 32,270 shares of the biopharmaceutical company’s stock worth $1,188,000 after buying an additional 3,100 shares during the period. American Century Companies Inc. acquired a new stake in shares of Theravance Biopharma during the first quarter worth about $1,132,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Theravance Biopharma by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 206,023 shares of the biopharmaceutical company’s stock worth $7,586,000 after buying an additional 5,188 shares during the period. 84.10% of the stock is owned by institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.